非小细胞肺癌中不断发展的免疫血管生成模式：来自ivonescimab的经验教训

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-05-06 DOI:10.1038/s41571-025-01024-y

Roy S. Herbst, Lieping Chen

{"title":"非小细胞肺癌中不断发展的免疫血管生成模式：来自ivonescimab的经验教训","authors":"Roy S. Herbst, Lieping Chen","doi":"10.1038/s41571-025-01024-y","DOIUrl":null,"url":null,"abstract":"The HARMONi-2 trial demonstrated a significant improvement in progression-free survival with ivonescimab, a bispecific PD-1×VEGF antibody, versus pembrolizumab in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Ivonescimab might enhance antitumour immunity by normalizing the tumour vasculature and reversing immunosuppression. Although promising, global applicability of ivonescimab awaits further validation, including overall survival results, in diverse populations.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"18 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab\",\"authors\":\"Roy S. Herbst, Lieping Chen\",\"doi\":\"10.1038/s41571-025-01024-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The HARMONi-2 trial demonstrated a significant improvement in progression-free survival with ivonescimab, a bispecific PD-1×VEGF antibody, versus pembrolizumab in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Ivonescimab might enhance antitumour immunity by normalizing the tumour vasculature and reversing immunosuppression. Although promising, global applicability of ivonescimab awaits further validation, including overall survival results, in diverse populations.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01024-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01024-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

HARMONi-2试验表明，与派姆单抗相比，ivonescimab（一种双特异性PD-1×VEGF抗体）在pd - l1阳性晚期非小细胞肺癌患者的无进展生存期有显著改善。Ivonescimab可能通过使肿瘤血管系统正常化和逆转免疫抑制来增强抗肿瘤免疫。尽管前景看好，但ivonescimab的全球适用性有待进一步验证，包括在不同人群中的总生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab

The HARMONi-2 trial demonstrated a significant improvement in progression-free survival with ivonescimab, a bispecific PD-1×VEGF antibody, versus pembrolizumab in patients with PD-L1-positive advanced-stage non-small-cell lung cancer. Ivonescimab might enhance antitumour immunity by normalizing the tumour vasculature and reversing immunosuppression. Although promising, global applicability of ivonescimab awaits further validation, including overall survival results, in diverse populations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.